Arevalo et al (see page 1605)

Intravitreal bevacizumab stabilizes BCVA in about 44% of the cases over the long-term and in the remainder, there may be a significant improvement or loss of BCVA. Systemic adverse events develop in 5.1% of patients.

Querques et al (see page 1611)

Outcomes of eyes with both neovascular age related macular degeneration and diabetic retinopathy showed stable or improved diabetic retinopathy severity with anti-vascular endothelial growth factor therapy.

McKibbin et al (see page 1617)

The likelihood of retreatment with ranibizumab for neovascular age-related macular degeneration reduces as the time without treatment increases. Nearly a third of eyes require retreatment within the next 12-months despite remaining injection-free for 12-months.

Sivaprasad et al (see page 1623)

Regression analysis of AURA revealed that a number of factors were predictive of treatment outcomes in a real-life setting, including age, baseline visual acuity score, number of injections, and regular monitoring.

Chhablani et al (see page 1629)

Off label use of ziv-aflibercept for wet age-related macular degeneration improves visual acuity, without any toxicity at …